Personalis Total Assets 2018-2026 | PSNL
Personalis total assets from 2018 to 2026. Total assets can be defined as the sum of all assets on a company's balance sheet.
|
Personalis Annual Total Assets (Millions of US $) |
|
|---|---|
| 2025 | $334 |
| 2024 | $270 |
| 2023 | $225 |
| 2022 | $293 |
| 2021 | $397 |
| 2020 | $245 |
| 2019 | $157 |
| 2018 | $42 |
| 2017 | $0 |
|
Personalis Quarterly Total Assets (Millions of US $) |
|
|---|---|
| 2026-03-31 | $325 |
| 2025-12-31 | $334 |
| 2025-09-30 | $243 |
| 2025-06-30 | $259 |
| 2025-03-31 | $273 |
| 2024-12-31 | $270 |
| 2024-09-30 | $240 |
| 2024-06-30 | $186 |
| 2024-03-31 | $195 |
| 2023-12-31 | $225 |
| 2023-09-30 | $227 |
| 2023-06-30 | $249 |
| 2023-03-31 | $272 |
| 2022-12-31 | $293 |
| 2022-09-30 | $318 |
| 2022-06-30 | $358 |
| 2022-03-31 | $381 |
| 2021-12-31 | $397 |
| 2021-09-30 | $407 |
| 2021-06-30 | $383 |
| 2021-03-31 | $396 |
| 2020-12-31 | $245 |
| 2020-09-30 | $249 |
| 2020-06-30 | $146 |
| 2020-03-31 | $152 |
| 2019-12-31 | $157 |
| 2019-09-30 | $160 |
| 2019-06-30 | $192 |
| 2019-03-31 | $0 |
| 2018-12-31 | $0 |
| 2018-09-30 | $0 |
| 2018-06-30 | $0 |
| 2017-12-31 | $0 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $0.630B | $0.070B |
| Personalis Inc. is a cancer genomics company. It is engaged in the development of therapies by providing molecular data about each patient's cancer and immune response. Personalis Inc. is based in Menlo Park, California. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $35.437B | 10.97 |
| BridgeBio Pharma (BBIO) | United States | $14.460B | 0.00 |
| Dr Reddy's Laboratories (RDY) | India | $11.109B | 17.29 |
| Aspen Pharmacare (APNHY) | South Africa | $3.708B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.918B | 22.33 |
| Bausch Health Cos (BHC) | Canada | $2.086B | 1.50 |
| Taysha Gene Therapies (TSHA) | United States | $1.290B | 0.00 |
| Amphastar Pharmaceuticals (AMPH) | United States | $0.924B | 7.28 |
| Assembly Biosciences (ASMB) | United States | $0.451B | 0.00 |
| Sol-Gel Technologies (SLGL) | Israel | $0.210B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.052B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |